PMX-30063: Phase Ib start

This quarter, PolyMedix will begin a placebo-controlled, Canadian Phase Ib trial to evaluate 5-10 doses of intravenous PMX-30063 given every 12, 24, or 48 hours in healthy volunteers. ...